Profile data is unavailable for this security.
About the company
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
- Revenue in SEK (TTM)0.00
- Net income in SEK-79.73m
- Incorporated2011
- Employees10.00
- LocationInfant Bacterial Therapeutics ABBryggargatan 10STOCKHOLM 111 21SwedenSWE
- Phone+46 841014555
- Websitehttps://ibtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corline Biomedical AB | 7.56m | -23.85m | 423.90m | 13.00 | -- | 5.25 | -- | 56.08 | -1.02 | -1.02 | 0.3142 | 3.15 | 0.0862 | -- | 10.59 | 581,461.60 | -27.20 | -8.36 | -29.49 | -9.10 | 82.54 | 121.50 | -315.49 | -53.37 | -- | -1,153.67 | 0.00 | -- | -60.95 | 55.82 | -1,182.15 | -- | 9.13 | -- |
| Biohit Oyj | 151.83m | 23.06m | 436.54m | 49.00 | 22.59 | 3.89 | 15.73 | 2.88 | 0.1488 | 0.1488 | 0.9375 | 0.8627 | 0.8955 | 4.67 | 2.72 | 310,500.00 | 14.23 | 0.344 | 17.87 | 0.4349 | 67.34 | 63.49 | 15.89 | 0.3814 | 2.54 | -- | 0.0966 | 0.00 | 9.23 | 7.28 | 38.74 | -- | 54.27 | -- |
| Enzymatica AB (publ) | 52.73m | -54.14m | 442.99m | 21.00 | -- | 3.26 | -- | 8.40 | -0.2257 | -0.2257 | 0.2198 | 0.559 | 0.292 | 1.26 | 4.54 | 2,510,953.00 | -29.98 | -29.10 | -31.26 | -34.48 | 63.76 | 63.82 | -102.68 | -73.32 | -- | -- | 0.0095 | -- | -10.47 | -5.76 | -6.94 | -- | -14.62 | -- |
| Moberg Pharma AB (publ) | 12.50m | -257.79m | 456.68m | 6.00 | -- | 0.651 | -- | 36.54 | -5.52 | -5.52 | 0.2672 | 14.40 | 0.0153 | 0.9991 | 1.87 | 1,388,556.00 | -31.46 | -- | -32.04 | -- | 52.35 | -- | -2,062.80 | -- | 15.81 | -- | 0.0044 | -- | -- | -- | -1,109.46 | -- | -- | -- |
| Navamedic ASA | 502.50m | -36.73m | 500.42m | 45.00 | -- | 2.56 | -- | 0.9959 | -2.21 | -2.21 | 27.98 | 8.74 | 0.883 | 3.27 | 6.40 | 12,843,290.00 | -6.45 | -0.3087 | -8.75 | -0.4895 | 37.32 | 39.37 | -7.31 | -0.2916 | 0.7697 | 0.192 | 0.5978 | -- | 3.80 | 23.00 | 59.92 | -- | 35.76 | -- |
| Dicot Pharma AB | 126.00k | -84.00m | 650.02m | 4.00 | -- | 7.20 | -- | 5,158.91 | -0.0459 | -0.0459 | 0.00007 | 0.0449 | 0.001 | 10.68 | 0.0371 | 42,000.00 | -69.50 | -94.78 | -75.43 | -111.46 | -61,341.27 | -32,616.05 | -66,663.49 | -37,576.05 | 8.82 | -- | 0.00 | -- | -88.60 | -47.16 | -30.66 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -79.73m | 744.64m | 10.00 | -- | 6.20 | -- | -- | -5.92 | -5.92 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.19 | -22.82 | -48.56 | -24.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.24 | -- | -- | -- |
| Cinclus Pharma Holding publ AB | 48.42m | -177.05m | 777.18m | 19.00 | -- | 1.84 | -- | 16.05 | -3.80 | -3.80 | 1.04 | 9.07 | 0.0777 | -- | 15.47 | 3,724,539.00 | -28.43 | -- | -32.01 | -- | -- | -- | -365.65 | -- | -- | -- | 0.0197 | -- | -23.14 | -- | 21.89 | -- | -- | -- |
| Vistin Pharma ASA | 423.71m | 72.72m | 826.20m | 77.00 | 11.36 | 2.84 | 8.90 | 1.95 | 1.76 | 1.76 | 10.26 | 7.05 | 1.12 | 1.87 | 6.20 | -- | 19.20 | 1.65 | 23.64 | 1.99 | 66.40 | 62.28 | 17.16 | 1.88 | 1.16 | -- | 0.063 | -- | -1.45 | 13.56 | 37.62 | -1.03 | 17.32 | -- |
| Arcticzymes Technologies ASA | 96.02m | 7.13m | 1.02bn | 55.00 | 146.82 | 3.32 | 66.53 | 10.65 | 0.1464 | 0.1464 | 1.97 | 6.47 | 0.2967 | 0.295 | 1.91 | 1,874,073.00 | 2.20 | 13.28 | 2.32 | 14.39 | 95.42 | 96.20 | 7.43 | 31.41 | 15.45 | -- | 0.0184 | 0.00 | -12.26 | 18.22 | -56.40 | -- | 53.98 | -- |
| Orexo AB | 386.40m | -201.10m | 1.03bn | 72.00 | -- | 2.10 | -- | 2.68 | -5.80 | 18.42 | 11.15 | 14.22 | 0.4073 | 1.29 | 2.02 | 5,366,667.00 | -21.20 | -28.03 | -29.75 | -42.57 | 89.96 | 83.88 | -52.04 | -74.89 | 3.70 | -3.00 | 0.5005 | -- | -12.46 | -47.69 | 15.63 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -106.27m | 1.10bn | 8.00 | -- | 5.67 | -- | -- | -2.20 | -2.20 | 0.00 | 3.65 | 0.00 | -- | -- | 0.00 | -45.16 | -85.38 | -50.22 | -99.19 | -- | -- | -- | -- | -- | -63.96 | 0.0071 | -- | -- | -- | 61.82 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Infant Bacterial Therapeutics AB's reporting currency: Swedish Krona SEK
24.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2025 | 1.34m | 10.32% |
| Premier Fund Managers Ltd.as of 30 Sep 2025 | 611.56k | 4.70% |
| �landsbanken Fondbolag AB (Sweden)as of 30 Jun 2025 | 446.64k | 3.43% |
| Banque Pictet & Cie SA (Investment Management)as of 30 Jun 2025 | 321.17k | 2.47% |
| Baader Bank AG (Investment Management)as of 28 Nov 2025 | 188.85k | 1.45% |
| SEB Funds ABas of 31 Dec 2025 | 85.94k | 0.66% |
| Handelsbanken Fonder ABas of 31 Dec 2025 | 76.20k | 0.59% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 46.30k | 0.36% |
| Skandia Investment Management ABas of 28 Nov 2025 | 13.17k | 0.10% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 350.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
